Your browser is no longer supported. Please, upgrade your browser.
Settings
OASM Oasmia Pharmaceutical AB (publ) daily Stock Chart
OASM [NASD]
Oasmia Pharmaceutical AB (publ)
Index- P/E- EPS (ttm)-0.29 Insider Own- Shs Outstand74.97M Perf Week1.75%
Market Cap173.92M Forward P/E- EPS next Y- Insider Trans- Shs Float61.20M Perf Month56.30%
Income- PEG- EPS next Q- Inst Own0.14% Short Float0.00% Perf Quarter2.20%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.00 Perf Half Y-22.92%
Book/sh0.61 P/B3.81 EPS next Y- ROA- Target Price6.00 Perf Year81.89%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.94 - 5.70 Perf YTD-23.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.00% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low143.04% ATR0.37
Employees60 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)58.52 Volatility11.65% 17.86%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.91 Prev Close2.32
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume244.75K Price2.28
Recom2.00 SMA2040.82% SMA5035.53% SMA200-20.32% Volume35,953 Change-1.72%
Sep-12-16Initiated Rodman & Renshaw Buy $6
Jul-11-19 09:30PM  Bragar Eagel & Squire, P.C. is Investigating Oasmia Pharmaceutical AB (NASDAQ: OASM) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire -20.80%
08:00PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire
04:59PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire
01:46PM  OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm GlobeNewswire
10:53AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Oasmia Pharmaceutical AB (OASM) ACCESSWIRE
Jul-10-19 06:22PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Oasmia Pharmaceutical AB - OASM Business Wire -13.08%
05:03PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Oasmia Pharmaceutical AB - OASM GlobeNewswire
Jul-08-19 01:50PM  A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019 Benzinga +13.43%
09:22AM  Company News for Jul 8, 2019 Zacks
Jun-28-19 02:46PM  OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm PR Newswire -23.81%
Jun-08-18 02:30AM  Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 April 30, 2018 GlobeNewswire +7.18%
Jun-05-18 02:30AM  Results from Oasmia Pharmaceuticals phase III study have been presented at ASCO annual meeting GlobeNewswire
May-30-18 11:45AM  Nexttobe Extends Loan to Oasmia Pharmaceutical GlobeNewswire -8.50%
May-21-18 02:30AM  Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc. GlobeNewswire -7.65%
May-17-18 02:30AM  Results from Oasmia Pharmaceuticals phase III study will be presented at ASCO annual meeting in June GlobeNewswire +6.52%
May-16-18 12:00PM  Notification from Oasmia Pharmaceutical GlobeNewswire
May-08-18 02:30AM  Notification from Oasmia Pharmaceutical AB GlobeNewswire -6.51%
May-02-18 02:45AM  Notification from Oasmia Pharmaceutical AB GlobeNewswire
Apr-24-18 02:00AM  Notification from Oasmia Pharmaceutical AB GlobeNewswire -12.09%
Apr-19-18 02:45AM  Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000 GlobeNewswire
Mar-02-18 02:30AM  Oasmia Pharmaceutical AB (publ) GlobeNewswire -6.75%
Feb-19-18 02:30AM  Oasmia Pharmaceuticals Docecal program achieves significant development milestone GlobeNewswire
Dec-06-17 09:25AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 6, 2017 Capital Cube
Sep-18-17 02:02PM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017 Capital Cube
Aug-08-17 07:00AM  Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia GlobeNewswire +13.00%
Jul-12-17 10:54AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017 Capital Cube +5.87%
Jun-14-17 07:00AM  Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets GlobeNewswire +5.98%
Mar-22-17 09:28AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017 Capital Cube
09:28AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017
Jan-23-17 07:00AM  Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division GlobeNewswire
Jan-19-17 11:53AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : January 19, 2017 Capital Cube
11:53AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : January 19, 2017
Dec-21-16 07:00AM  Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®) GlobeNewswire
Dec-07-16 09:30AM  Oasmia Pharmaceutical ABs Warrant Programs Fully Subscribed GlobeNewswire
Dec-06-16 10:01AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : December 6, 2016 Capital Cube
10:01AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : December 6, 2016
Dec-02-16 10:05AM  Interim report for the period May - October 2016 GlobeNewswire
Nov-22-16 07:49AM  Communiqué from Extraordinary General Meeting 2016 GlobeNewswire
Nov-02-16 07:24AM  Nexttobe Extends Loan to Oasmia Pharmaceutical GlobeNewswire
Oct-31-16 02:32PM  Oasmia Buys Estrogen Receptor Cancer Drug (OASM) at Investopedia
07:25AM  Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ) GlobeNewswire
Oct-26-16 07:07AM  Oasmia convenes an extraordinary general meeting on the 21 November, 2016 GlobeNewswire
Oct-25-16 07:30AM  Oasmia Pharmaceutical AB Well Positioned for Growth Following Collaborative Agreement, Funding Announcements, and Newly Proposed Executive Leadership GlobeNewswire
Oct-24-16 07:28AM  Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million GlobeNewswire
07:14AM  Oasmia successfully completes private placement of SEK 70 million GlobeNewswire
07:11AM  Oasmia Pharmaceutical intends to convene an extraordinary general meeting GlobeNewswire
07:08AM  Oasmia enters into collaboration agreement for novel cancer project GlobeNewswire
Oct-22-16 08:43AM  Oasmia announces private placement of new shares GlobeNewswire
Oct-21-16 04:13PM  Oasmia in discussions concerning acquisition of novel cancer project GlobeNewswire
Sep-27-16 07:04AM  Communique from Oasmia's Annual General Meeting 2016 GlobeNewswire
Sep-12-16 07:11AM  Coverage initiated on Oasmia Pharmaceutical by Rodman & Renshaw
Sep-06-16 09:27AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2017 By the Numbers : September 6, 2016 Capital Cube
09:27AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2017 By the Numbers : September 6, 2016
Sep-02-16 09:36AM  Interim report for the period May - July 2016 GlobeNewswire
Aug-31-16 01:04PM  OASMIA PHARMACEUTICAL AB Financials
07:05AM  Oasmia Pharmaceutical AB Appoints Fredrik Gynnerstedt as Chief Financial Officer GlobeNewswire
Jun-10-16 07:20AM  Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000 GlobeNewswire
Jun-03-16 08:05AM  Oasmia Pharmaceutical reports 4Q loss
07:24AM  Year-end report for the fiscal year May 1, 2015 - April 30, 2016 GlobeNewswire
May-26-16 07:12AM  Oasmia Pharmaceutical to Identify International Partners for Marketing, Distribution and new Product Development based on the Company's Nanotechnology XR17 GlobeNewswire
Apr-27-16 07:27AM  Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer GlobeNewswire
07:00AM  Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer PR Newswire
Apr-05-16 08:10AM  Oasmia Pharmaceutical Reports Positive Clinical Study Results for Proprietary XR17 Nanotechnology GlobeNewswire
Mar-30-16 07:42AM  Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel GlobeNewswire
02:54AM  Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel at noodls
Mar-10-16 07:07AM  Oasmia Pharmaceutical Seeks to Fill Void in Ovarian Cancer Treatment Market Indicated in Recent National Academy of Medicine Report GlobeNewswire
Mar-03-16 07:24AM  Interim report for the period May 2015 - January 2016 GlobeNewswire
Feb-24-16 08:45AM  Oasmia Pharmaceutical AB Provides Updates to Clinical Program Development GlobeNewswire
Feb-08-16 07:38AM  Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea(r) (Paclical(r)) GlobeNewswire
07:22AM  Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea(R) (Paclical(R)) PR Newswire
07:00AM  Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®) PR Newswire
Feb-02-16 02:36AM  Oasmia Pharmaceutical Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase at noodls
Jan-11-16 07:33AM  Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11 GlobeNewswire
Jan-08-16 10:00AM  Oasmia Pharmaceutical to Ring the Nasdaq Stock Market Opening Bell GlobeNewswire
Jan-04-16 07:06AM  Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos(r) in Russia GlobeNewswire
Dec-07-15 07:05AM  Oasmia Pharmaceutical's Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials GlobeNewswire
Dec-03-15 07:07AM  Interim report for the period May - October 2015 GlobeNewswire
Nov-20-15 07:07AM  Oasmia Pharmaceutical's Lead Human Cancer Drug Paclical(r) Generates Strong Interest at the 19th Annual Russian Cancer Congress GlobeNewswire
Nov-05-15 11:40AM  Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment GlobeNewswire
07:05AM  Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical(r) From Head-to-Head Comparison Study with Abraxane(r) GlobeNewswire
07:00AM  Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane® PR Newswire
Nov-04-15 09:30AM  Oasmia Chairman on Share Offering: 'We Went at a Bad Time' at The Wall Street Journal
Oct-30-15 07:00AM  Oasmia Pharmaceutical Receives Order of $7.5 Million in End-user Value for the Russian Market PR Newswire
Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paclical/Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications. It also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for mammary carcinoma and squamous cell carcinoma; and Doxophos Vet for lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is based in Uppsala, Sweden.